Search research articles
Contact Us
Filters
Showing results (11-20 of 129) with videos related to
Page
of 13
Sort By:
Plos One
|
January 24, 2014
Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis
Jared B Ditkowsky, Kevin Schwartzman
American Journal of Respiratory and Critical Care Medicine
|
September 3, 2011
Caveat emptor? Control of latent tuberculosis infection in the United States
Kevin Schwartzman, Kevin P Cain
American Journal of Epidemiology
|
July 3, 2021
Invited Commentary: The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination
Jonathon R Campbell, Kevin Schwartzman
BMC Public Health
|
June 7, 2008
Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis
Michael Tan, Dick Menzies, Kevin Schwartzman
Technology and Culture
|
February 21, 2009
Collapse and expand: architecture and tuberculosis therapy in Montreal, 1909, 1933, 1954
Annmarie Adams, Kevin Schwartzman, David Theodore
Lancet (London, England)
|
July 2, 2013
Tuberculosis vaccine trials
Marcel A Behr, Kevin Schwartzman, Madhukar Pai
American Journal of Respiratory and Critical Care Medicine
|
July 28, 2021
The Lobe That Got Away
Amr J Alwakeel, Christian Sirois, Kevin Schwartzman
Plos Medicine
|
June 7, 2019
Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries
Jonathon R Campbell, David Dowdy, Kevin Schwartzman
Plos One
|
May 6, 2016
Latent Tuberculosis in Pregnancy: A Systematic Review
Isabelle Malhamé, Maxime Cormier, Jordan Sugarman, et al.
Expert Review of Respiratory Medicine
|
July 28, 2010
Earthquake in Haiti: is the Latin American and Caribbean region's highest tuberculosis rate destined to become higher?
Faiz A Khan, Benjamin M Smith, Kevin Schwartzman
Page
of 13
Search research articles
Search
Showing results (11-20 of 129) with videos related to
Sort By:
Page
of 13
Plos One
|
January 24, 2014
Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis
Jared B Ditkowsky, Kevin Schwartzman
American Journal of Respiratory and Critical Care Medicine
|
September 3, 2011
Caveat emptor? Control of latent tuberculosis infection in the United States
Kevin Schwartzman, Kevin P Cain
American Journal of Epidemiology
|
July 3, 2021
Invited Commentary: The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination
Jonathon R Campbell, Kevin Schwartzman
BMC Public Health
|
June 7, 2008
Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis
Michael Tan, Dick Menzies, Kevin Schwartzman
Technology and Culture
|
February 21, 2009
Collapse and expand: architecture and tuberculosis therapy in Montreal, 1909, 1933, 1954
Annmarie Adams, Kevin Schwartzman, David Theodore
Lancet (London, England)
|
July 2, 2013
Tuberculosis vaccine trials
Marcel A Behr, Kevin Schwartzman, Madhukar Pai
American Journal of Respiratory and Critical Care Medicine
|
July 28, 2021
The Lobe That Got Away
Amr J Alwakeel, Christian Sirois, Kevin Schwartzman
Plos Medicine
|
June 7, 2019
Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries
Jonathon R Campbell, David Dowdy, Kevin Schwartzman
Plos One
|
May 6, 2016
Latent Tuberculosis in Pregnancy: A Systematic Review
Isabelle Malhamé, Maxime Cormier, Jordan Sugarman, et al.
Expert Review of Respiratory Medicine
|
July 28, 2010
Earthquake in Haiti: is the Latin American and Caribbean region's highest tuberculosis rate destined to become higher?
Faiz A Khan, Benjamin M Smith, Kevin Schwartzman
Page
of 13